Romidepsin
Who holds supplier records for Romidepsin? 3 organisations hold a current record for Romidepsin: an active US FDA Type II Drug Master File. A further 2 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (2) and Netherlands (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Romidepsin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/romidepsin
Reading the evidence
- 3 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
2 of the 3 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 2 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
Current records (3)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Romidepsin. Country is the organisation's recorded country, not necessarily the manufacturing site.
- CONCORD BIOTECH LTDIndia Company GMP cert on recordActive DMF 27399 · latest filing Nov 2013
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 33497 · latest filing Jan 2019
- TAPI NL BVNetherlandsActive DMF 27400 · latest filing Sept 2013
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (2)
Organisations whose Type II DMFs for Romidepsin are no longer active. These show a past filing, not current supply.
Show all 2 historical records
- China · Inactive DMF 33235 · filed Sept 2018
- United States · Inactive DMF 12079 · filed Aug 1996
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (4 listed products contain Romidepsin). The latest listed exclusivity runs to 7 Dec 2026. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Romidepsin is a cyclic peptide inhibitor of histone deacetylase, used in the treatment of various types of cancer, including cutaneous T-cell lymphoma. It works by increasing the acetylation of histone proteins, leading to cell cycle arrest and apoptosis in cancer cells.
Chemical identity
- IUPAC name
- (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
- Canonical SMILES
- C/C=C\1/C(=O)N[C@H](C(=O)O[C@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C
- InChIKey
- OHRURASPPZQGQM-GCCNXGTGSA-N
- Synonyms
- Istodax API, chromadax, depsipeptide, fk-228, fk228, fr-901228, fr901228, istodax, nsc-630176
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Histone Deacetylase Inhibitor
- Mechanism of action
- Bile Salt Export Pump Inhibitors; Histone Deacetylase Inhibitors; Organic Anion Transporter 1 Inhibitors; Organic Anion Transporting Polypeptide 1B1 Inhibitors; Organic Anion Transporting Polypeptide 1B3 Inhibitors; Organic Cation Transporter 2 Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Romidepsin?
3 organisations hold an active US FDA Type II Drug Master File or a CEP for Romidepsin: CONCORD BIOTECH LTD (India), MSN Laboratories Private Limited (India) and TAPI NL BV (Netherlands). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Romidepsin Drug Master Files are active?
CONCORD BIOTECH LTD (DMF 27399), MSN Laboratories Private Limited (DMF 33497) and TAPI NL BV (DMF 27400). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Romidepsin records mean?
2 organisations have only inactive Type II DMFs for Romidepsin. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
How do I qualify a Romidepsin supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Romidepsin?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.